Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.
AIDS. 2014; 28: 1193-1202
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Nature. 1997; 387: 183-188
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
Nat Med. 1999; 5: 512-517
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.
Nature. 2014; 512: 74-77
Re-emergence of HIV after stopping therapy.
Nature. 1999; 401: 874-875
HIV DNA set point is rapidly established in acute HIV infection and dramatically reduced by early ART.
EBioMedicine. 2016; 11: 68-72
HIV-1 DNA predicts disease progression and post-treatment virological control.
eLife. 2014; 3e03821
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.
AIDS. 2016; 30: 343-353
Proviral latency, persistent human immunodeficiency virus infection, and the development of latency reversing agents.
J Infect Dis. 2017; 215: S111-S118
HIV: Shock and kill.
Nature. 2012; 487: 439-440
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Nature. 2012; 487: 482-485
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
PLoS Pathog. 2014; 10e1004473
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.
Lancet HIV. 2014; 1: e13-e21
Modeling the effects of vorinostat in vivo reveals both transient and delayed HIV transcriptional activation and minimal killing of latently infected cells.
PLoS Pathog. 2015; 11e1005237
Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1?.
Retrovirology. 2012; 9: 72
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
Mol Ther. 2014; 22: 464-475
Therpaeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study).
EClinicalMedicine. 2019; 11: 65-80
Mothe B, Manzardo C. Sanchez-Bernabeu, et al. Viral control induced by HIVConsv vaccines and romidepsin in early treated individuals. Conference on Retrovirsuses and Opportunitistic Infections; Seattle, WA, USA; Feb 13–16, 2017 (abstr 119LB).
Infection staging and incidence surveillance applications of high dynamic range diagnostic immuno-assay platforms.
J Acquir Immune Defic Syndr. 2017; 76: 547-555
Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.
AIDS. 2001; 15: 665-673
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
J Clin Invest. 2017; 127: 3126-3135
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2016.
Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, ‘definetherain’.
J Virol Methods. 2014; 202: 46-53
Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.
AIDS. 2012; 26: 2295-2306
Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA.
PLoS One. 2014; 9e85999
A highly reproducible quantitative viral outgrowth assay for the measurement of the replication-competent latent HIV-1 reservoir.
Sci Rep. 2017; 743231
A Novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection.
Front Immunol. 2019; 93175
Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection.
J Infect Dis. 2012; 206: 552-561
DAIDS adverse event grading tables.
HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.
JCI Insight. 2017; 2e92901
McMahon DJ, Zheng L, Cyktor J, et al. Multidose IV romidepsin: no increased HIV-1 expression in persons on ART: ACTGA5315. Conference on Retrovirsuses and Opportunitistic Infections; Seattle, WA, USA; March 3–6, 2019 (abstr 26).
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
Lancet HIV. 2016; 3: e463-e472
Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.
AIDS. 2017; 31: 181-189
The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
Sci Rep. 2016; 630749
Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.
AIDS. 2019; 33: 425-431
Mothe B, Moltó J, Manzardo C, et al. Viral control induced by HIVconsv vaccines & romidepsin in early treated individuals. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA Feb 14, 2017 (abstr 119LB).
Measuring the size of the latent human immunodeficiency virus reservoir: the present and future of evaluating eradication strategies.
J Infect Dis. 2017; 215: S134-S141
Lessons learned from HIV antiretroviral treatment interruption trials.
Curr Opin HIV AIDS. 2018; 13: 416-421
Towards an HIV-1 cure: measuring the latent reservoir.
Trends Microbiol. 2015; 23: 192-203
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting.
Lancet HIV. 2019; 6: e259-e268
